Media & Resources

IAVI’s Board, management and staff extend their deepest sympathy and best wishes to those adversely affected by Hurricane Sandy. IAVI’s offices at 125 Broad Street in New York City, located near the East River, are temporarily closed owing to the damage to the building from the storm. We are in the process of relocating as…

MVI, International AIDS Vaccine Initiative, and Imperial College London  Establish Collaboration to Guide Selection and Prioritization of  Malaria Vaccine Candidates  WASHINGTON, DC (20 August 2012)—In response to a critical gap in developing malaria vaccines, the PATH Malaria Vaccine Initiative (MVI) announced a new collaboration today with the International AIDS Vaccine Initiative (IAVI) and Imperial College…

New Delhi, August 13, 2012—Former President of India, the Honourable Dr APJ Abdul Kalam inaugurated the International Symposium, “Accelerating India’s Response to Research for a Preventive HIV Vaccine”, devoted exclusively to HIV vaccine design and development, held today at the New Delhi Municipal Council (NDMC) Convention Centre. The two-day symposium has been organized by the…

NEW YORK, NY, July 31, 2012—The International AIDS Vaccine Initiative (IAVI) today announced the appointment to its Board of Directors of Alice P. Albright, Executive Vice President and Chief Operating Officer of the Export-Import Bank of the United States, and Dr. Purnima Mane, President and Chief Executive Officer of Pathfinder International. They join a diverse…

Report released at AIDS 2012 calls for sustained funding of HIV prevention research to achieve our collective vision of zero new HIV infections Washington DC (23 July 2012) – A decade of unprecedented investment in HIV prevention research has led to major scientific breakthroughs in vaccines, microbicides, voluntary medical male circumcision, treatment as prevention and…

Partnership to accelerate development of vaccines against the world’s deadliest infectious diseases, tuberculosis and HIV July 17, 2012—New York, New York and Rockville, MD— Aeras and the International AIDS Vaccine Initiative (IAVI) are pleased to announce the expansion of their existing partnership through a formal collaboration agreement. The two nonprofit organizations, which focus on tuberculosis (TB)…

New York, July 16, 2012—The International AIDS Vaccine Initiative applauds the U.S. Food and Drug Administration (FDA) for its decision to approve the combination anti-retroviral (ARV) drug Truvada for the prevention of HIV. More than 7,400 individuals worldwide are newly infected with HIV every day, and several studies have shown that ARV-based pre-exposure prophylaxis (PrEP)…

New York, July 11, 2012—The International AIDS Vaccine Initiative warmly congratulates The Scripps Research Institute and Duke University for winning major grants from the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Disease (NIAID) to support the design and development of preventive HIV vaccines. The Center for HIV/AIDS Vaccine Immunology & Immunogen…